Gait Profile Score in Children With Cerebral Palsy (CP): Influence of the CP Type, Treatment With Botulinum Injection and Multilevel Surgery
Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE SAINT ETIENNE · Jul 11, 2024
Trial Information
Current as of July 22, 2025
Completed
Keywords
ClinConnect Summary
This clinical trial is studying how different types of cerebral palsy (CP) affect walking patterns in children and how treatments like botulinum injections and multilevel surgery can improve their movement. Researchers are using a special method called three-dimensional gait analysis (3DGA) to record how children walk, which helps them understand the specific challenges each child faces. They will measure the quality of the walking patterns using a score called the Gait Profile Score (GPS), which simplifies complex data into one easy-to-understand number.
To participate in this study, children must be between 6 and 18 years old and have a diagnosed form of cerebral palsy, whether it’s unilateral (affecting one side), bilateral (both sides), triplegic, or quadriplegic. They should have a Gross Motor Function Classification System score of I to III, indicating varying levels of mobility. Participants should not have received botulinum toxin injections or other treatments in the three months before the study. Those who join can expect to undergo detailed gait analysis to help doctors gain insights into their walking patterns and the potential benefits of different treatments.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Etiology of cerebral palsy
- • Unilateral, bilateral, triplegic or quadriplegic forms of cerebral palsy.
- • 6 to 18 years old
- • GMFCS (Gross Motor Function Classification System) I to III
- • Instrumented gait analysis of the laboratory of St-Etienne
- • Absence of botulinum toxin injection or serial casting in the three months after a first instrumented gait analysis.
- Exclusion Criteria:
- • Etiology others than cerebral palsy as defined classically (ex: ischemic infarcts in a child older than two years).
- • Previous surgery in lower-limb.
About Centre Hospitalier Universitaire De Saint Etienne
The Centre Hospitalier Universitaire (CHU) de Saint-Étienne is a leading academic medical center in France, dedicated to advancing healthcare through innovative clinical research and high-quality patient care. With a robust infrastructure that supports a wide range of medical specialties, CHU de Saint-Étienne fosters collaboration between healthcare professionals, researchers, and academic institutions. The center is committed to conducting rigorous clinical trials that adhere to ethical standards and regulatory requirements, aiming to improve treatment outcomes and enhance the overall health of the community. Through its dedication to scientific excellence and patient-centered care, CHU de Saint-Étienne plays a pivotal role in the advancement of medical knowledge and the development of new therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Saint Etienne, , France
Patients applied
Trial Officials
Clément BOULARD, physiotherapist
Principal Investigator
CHU de Saint-Etienne
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported